BR112022002309A2 - Conjugado e usos do mesmo - Google Patents
Conjugado e usos do mesmoInfo
- Publication number
- BR112022002309A2 BR112022002309A2 BR112022002309A BR112022002309A BR112022002309A2 BR 112022002309 A2 BR112022002309 A2 BR 112022002309A2 BR 112022002309 A BR112022002309 A BR 112022002309A BR 112022002309 A BR112022002309 A BR 112022002309A BR 112022002309 A2 BR112022002309 A2 BR 112022002309A2
- Authority
- BR
- Brazil
- Prior art keywords
- conjugate
- treatment
- present
- therapeutic molecule
- peptide carrier
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
- A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1911403.2A GB201911403D0 (en) | 2019-08-09 | 2019-08-09 | Conjugate and uses thereof |
| PCT/GB2020/051891 WO2021028666A1 (en) | 2019-08-09 | 2020-08-07 | Conjugate and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022002309A2 true BR112022002309A2 (pt) | 2022-04-26 |
Family
ID=67990936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022002309A BR112022002309A2 (pt) | 2019-08-09 | 2020-08-07 | Conjugado e usos do mesmo |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220275372A1 (https=) |
| EP (1) | EP4010030A1 (https=) |
| JP (1) | JP7678654B2 (https=) |
| KR (1) | KR20220079524A (https=) |
| CN (2) | CN114615998B (https=) |
| AU (1) | AU2020327659A1 (https=) |
| BR (1) | BR112022002309A2 (https=) |
| CA (1) | CA3149700A1 (https=) |
| GB (1) | GB201911403D0 (https=) |
| IL (1) | IL290424A (https=) |
| MX (1) | MX2022001712A (https=) |
| SA (1) | SA522431627B1 (https=) |
| WO (1) | WO2021028666A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200131231A1 (en) | 2017-02-17 | 2020-04-30 | Oxford University Innovation Limited | Cell penetrating peptides |
| GB201812980D0 (en) | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| GB201812972D0 (en) | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| US12465646B2 (en) | 2018-12-07 | 2025-11-11 | Oxford University Innovation Limited | Linkers |
| WO2022171972A1 (en) * | 2021-02-12 | 2022-08-18 | Oxford University Innovation Limited | Cell-penetrating peptide conjugates and methods of their use |
| EP4304657A4 (en) * | 2021-03-12 | 2026-04-01 | Pepgen Inc | METHODS OF TREATMENT OF TYPE 1 MYOTONIC DYSTROPHY USING PEPTIDE-OLIGONUCLEOTIDE CONJUGATES |
| KR20250116673A (ko) * | 2022-11-21 | 2025-08-01 | 펩젠 인크. | 세포-침투 펩티드, 그의 접합체 및 그의 사용 방법 |
| WO2025033255A1 (ja) * | 2023-08-07 | 2025-02-13 | 東亞合成株式会社 | ペプチドフラグメント及びその利用 |
| WO2025033256A1 (ja) * | 2023-08-07 | 2025-02-13 | 東亞合成株式会社 | ペプチドフラグメント及びその利用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2049664T1 (sl) * | 2006-08-11 | 2012-04-30 | Prosensa Technologies Bv | Enojna veriga oligonukleotidov, komplementarna repetitivnim elementom, za zdravljenje genetskih bolezni, povezanih z nestabilnostjo dnk ponovitev |
| WO2009005793A2 (en) * | 2007-06-29 | 2009-01-08 | Avi Biopharma, Inc. | Tissue specific peptide conjugates and methods |
| US20100016215A1 (en) * | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| WO2009147368A1 (en) * | 2008-06-04 | 2009-12-10 | Medical Research Council | Peptides |
| US20110269665A1 (en) * | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| CN103998458B (zh) * | 2011-08-30 | 2018-10-09 | 医学研究理事会 | 具有中央疏水域的细胞穿透肽 |
| EP2900821B1 (en) * | 2012-09-25 | 2020-04-01 | Genzyme Corporation | Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy |
| RU2708237C2 (ru) | 2014-08-22 | 2019-12-05 | Общество с ограниченной ответственностью "НооГен" | Модифицированные олигонуклеотиды и способ их получения |
-
2019
- 2019-08-09 GB GBGB1911403.2A patent/GB201911403D0/en not_active Ceased
-
2020
- 2020-08-07 AU AU2020327659A patent/AU2020327659A1/en active Pending
- 2020-08-07 JP JP2022507761A patent/JP7678654B2/ja active Active
- 2020-08-07 CN CN202080071067.8A patent/CN114615998B/zh active Active
- 2020-08-07 CA CA3149700A patent/CA3149700A1/en active Pending
- 2020-08-07 MX MX2022001712A patent/MX2022001712A/es unknown
- 2020-08-07 KR KR1020227007655A patent/KR20220079524A/ko active Pending
- 2020-08-07 EP EP20754817.3A patent/EP4010030A1/en active Pending
- 2020-08-07 CN CN202510582562.XA patent/CN120837670A/zh active Pending
- 2020-08-07 WO PCT/GB2020/051891 patent/WO2021028666A1/en not_active Ceased
- 2020-08-07 BR BR112022002309A patent/BR112022002309A2/pt unknown
- 2020-08-07 US US17/631,654 patent/US20220275372A1/en active Pending
-
2022
- 2022-02-07 IL IL290424A patent/IL290424A/en unknown
- 2022-02-08 SA SA522431627A patent/SA522431627B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN114615998A (zh) | 2022-06-10 |
| US20220275372A1 (en) | 2022-09-01 |
| JP2022543320A (ja) | 2022-10-11 |
| JP7678654B2 (ja) | 2025-05-16 |
| KR20220079524A (ko) | 2022-06-13 |
| CA3149700A1 (en) | 2021-02-18 |
| AU2020327659A1 (en) | 2022-02-24 |
| EP4010030A1 (en) | 2022-06-15 |
| CN114615998B (zh) | 2025-05-23 |
| SA522431627B1 (ar) | 2024-05-19 |
| GB201911403D0 (en) | 2019-09-25 |
| CN120837670A (zh) | 2025-10-28 |
| WO2021028666A1 (en) | 2021-02-18 |
| MX2022001712A (es) | 2022-05-13 |
| IL290424A (en) | 2022-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022002309A2 (pt) | Conjugado e usos do mesmo | |
| TW200738877A (en) | Immunostimulatory oligoribonucleotides | |
| BR112014026703A2 (pt) | inibidores de dna-pk | |
| NZ543467A (en) | The severe acute respiratory syndrome coronavirus | |
| BRPI0511479A (pt) | molécula de ligação tendo atividade neutralizadora do vìrus da raiva, variante funcional de uma molécula de ligação, imunoconjugado, molécula de ácido nucléico, vetor, hospedeiro, método para produzir uma molécula de ligação ou uma variante funcional, composição farmacêutica, uso de uma molécula de ligação, uma variante funcional, um imunoconjugado como, ou uma composição, kit, método para identificar uma molécula de ligação ou uma molécula de ácido nucléico, e, coleção de moléculas de ligação humanas na superfìcie de pacotes genéticos replicáveis | |
| EA201992081A1 (ru) | Конъюгирование цитотоксических лекарственных средств посредством бис-связывания | |
| MX2012002502A (es) | Conjugados de polietilenglicol/peptidos enlazados por disulfuro para la transfeccion de acidos nucleicos. | |
| MX2010005631A (es) | Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades. | |
| ATE485304T1 (de) | Muteine von tearlipocalin und verfahren zu deren gewinnung | |
| MX2015005328A (es) | Composiciones y metodos para la administracion selectiva de moleculas de oligonucleotidos a tipos de celulas. | |
| BR112019001253A2 (pt) | composto, composição farmacêutica, e, métodos de tratamento de câncer ou de atrofia muscular e de doença de parkinson. | |
| CU20080028A6 (es) | Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus | |
| BRPI0519593A2 (pt) | composto, mÉtodos de tratar distérbios neurodegenerativos e complicaÇÕes devido a derrame ou trauma na cabeÇa, e de preparar um composto, e, uso de um composto | |
| AU2017250507A8 (en) | Methods of treatment using chlorotoxin conjugates | |
| UA103901C2 (ru) | Замещенные производные сульфамидов | |
| EA201200519A1 (ru) | Стабилизированные жидкие и лиофилизированные композиции adamts13 | |
| CO2024006160A2 (es) | Conjugado de anticuerpo bispecífico-fármaco de camptotecina y uso farmacéutico de este | |
| CY1117705T1 (el) | Νεες ενωσεις διυποκατεστημενης 3,4-διαμινο-3-κυκλοβουτενο-διονης-1,2 για χρηση στην θεραπεια προκαλουμενων απο χημειοκινη ασθενειων | |
| BR112015018491A2 (pt) | triterpenoides c-19-modificados com atividade inibidora de maturação de hiv | |
| CL2024001372A1 (es) | Conjugados que comprenden fósforo (v) y una fracción molecular de droga | |
| BR112021025394A2 (pt) | Derivados de antraciclina, conjugados de fármaco e molécula de ligação ao alvo, uso de conjugado de fármaco e molécula de ligação ao alvo, método de tratamento de uma doença em um paciente em necessidade de tratamento, e composição farmacêutica | |
| BR112014011333A2 (pt) | derivados de pregenen-11ss-17-21-triol-3,20-diona para o tratamento de condições oculares | |
| BRPI0513278A (pt) | uso de um composto, composto, composição farmacêutica, processo para produzir um composto, e, método para causar a morte celular através de terapia de ativação por fóton | |
| BRPI0508177A (pt) | composto, processo para a produção do composto, composição farmacêutica, uso do composto método para o tratamento de uma doença e produto de combinação | |
| MX337358B (es) | Conjugados de disorazoles y sus derivados con moleculas de union con celulas, nuevos derivados de disorazol, procesos de fabricacion y usos de los mismos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |